{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:41:30Z","timestamp":1791240090618,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,20]]},"DOI":"10.18632\/oncotarget.5600","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"33612-33622","source":"Crossref","is-referenced-by-count":26,"title":["The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory\/relapsed acute myeloid leukemia patients"],"prefix":"10.18632","volume":"6","author":[{"given":"Xuejie","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxin","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"},{"name":"Hematopathy Diagnosis and Therapy Center, Kanghua Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[{"name":"Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyi","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"},{"name":"Hematopathy Diagnosis and Therapy Center, Kanghua Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Arber","year":"2009","journal-title":"Blood"},{"key":"2","first-page":"1324","article-title":"DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias","volume":"87","author":"L\u00fcbbert","year":"2002","journal-title":"Haematologica"},{"key":"3","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V97.9.2823","article-title":"Methylation profiling in acute myeloid leukemia","volume":"97","author":"Issa","year":"2001","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3109\/10428194.2012.762093","article-title":"Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"54","author":"Roboz","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.hoc.2010.02.007","article-title":"Epigenetic changes in the myelodysplastic syndrome","volume":"24","author":"Issa","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"6","first-page":"567","article-title":"Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia","volume":"29","author":"Nicolet","year":"2014","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"crossref","first-page":"e51527","DOI":"10.1371\/journal.pone.0051527","article-title":"High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia","volume":"7","author":"Salles","year":"2012","journal-title":"PLoS One"},{"key":"8","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Kefauver","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter,. Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"DiPersio","year":"2010","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","article-title":"Effect of cytarabine and decitabine in combination in human leukemic cell lines","volume":"13","author":"Issa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1479-5876-12-167","article-title":"Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target","volume":"12","author":"Tong","year":"2014","journal-title":"J Transl Med"},{"key":"12","first-page":"djt440","article-title":"Synergistic targeting of AML stem\/progenitor cells with IAP antagonist birinapant and demethylating agents","volume":"106","author":"Kornblau","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","article-title":"Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML","volume":"118","author":"Feldman","year":"2011","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia","volume":"15","author":"Dierov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"15","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Pileri","year":"2010","journal-title":"Pathologica"},{"key":"16","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Appelbaum","year":"2000","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Biondi","year":"2003","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V97.5.1172","article-title":"Expression of DNA methyltransferases DNMT1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia","volume":"97","author":"Sasaki","year":"2001","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/febs.13142","article-title":"Epigenetic alterations in acute myeloid leukemias","volume":"282","author":"Minucci","year":"2015","journal-title":"FEBS J"},{"key":"20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3892\/ijo.2014.2792","article-title":"5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation","volume":"46","author":"Tschanter","year":"2015","journal-title":"Int J Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.18632\/oncotarget.2131","article-title":"A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12032-011-9916-x","article-title":"Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report","volume":"29","author":"Peller","year":"2012","journal-title":"Med Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.18632\/oncotarget.1559","article-title":"High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukemia","volume":"5","author":"Lane","year":"2014","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"crossref","first-page":"e53003","DOI":"10.1371\/journal.pone.0053003","article-title":"Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation","volume":"7","author":"Spinella","year":"2012","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/onc.2009.62","article-title":"DNA methylation inhibits p53-mediated survivin repression","volume":"28","author":"Loose","year":"2009","journal-title":"Oncogene"},{"key":"26","doi-asserted-by":"crossref","first-page":"e95588","DOI":"10.1371\/journal.pone.0095588","article-title":"Curcumin significantly enhances dual PI3K\/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in humanrenal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability","volume":"9","author":"Kwon","year":"2014","journal-title":"PLoS One"},{"key":"27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.cmet.2013.09.013","article-title":"mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc","volume":"18","author":"Yang","year":"2013","journal-title":"Cell Metab"},{"key":"28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","article-title":"Gene body methylation can alter gene expression and is a therapeutic target in cancer","volume":"26","author":"Liang","year":"2014","journal-title":"Cancer Cell"},{"key":"29","first-page":"e1152","article-title":"Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers","volume":"5","author":"Scheinberg","year":"2004","journal-title":"Cell Death Dis"},{"key":"30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.stem.2014.08.001","article-title":"SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute Myeloid Leukemia stem cells","volume":"15","author":"Yuan","year":"2014","journal-title":"Cell Stem Cell"},{"key":"31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","article-title":"c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clml.2014.10.003","article-title":"Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia","volume":"15","author":"Espigado","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"33","doi-asserted-by":"crossref","first-page":"e105381","DOI":"10.1371\/journal.pone.0105381","article-title":"Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neo.2014.05.009","article-title":"5-aza-2\u2032-deoxycytidine-mediated c-myc Down-regulation triggers telomere-dependent senescence by regulatinghuman telomerase reverse transcriptase in chronic myeloid leukemia","volume":"16","author":"Diederich","year":"2014","journal-title":"Neoplasia"},{"key":"35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Greally","year":"2010","journal-title":"Cancer Cell"},{"key":"36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Pardee","year":"2014","journal-title":"Ann Hematol"},{"key":"37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Heil","year":"2012","journal-title":"Haematologica"},{"key":"38","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.18632\/oncotarget.3361","article-title":"Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia","volume":"6","author":"Shi","year":"2015","journal-title":"Oncotarget"},{"key":"39","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-012-1550-y","article-title":"Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin\/cytarabine for patients with refractory acute myeloid leukemia","volume":"91","author":"Li","year":"2012","journal-title":"Ann Hematol"},{"key":"40","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/leu.2012.153","article-title":"A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","volume":"26","author":"Issa","year":"2012","journal-title":"Leukemia"},{"key":"41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00277-013-1758-5","article-title":"Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory\/relapsed acute myeloid leukemia: a single-center experience","volume":"92","author":"Jin","year":"2013","journal-title":"Ann Hematol"},{"key":"42","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.29367","article-title":"Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"121","author":"Brandt","year":"2015","journal-title":"Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:21:36Z","timestamp":1599610896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":42,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015,10,20]]}},"alternative-id":["5600","26384351"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5600","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}